Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;3(1):1-9.
doi: 10.1007/s40495-016-0078-6. Epub 2017 Jan 3.

Impact of Drug Treatment at Neonatal Ages on Variability of Drug Metabolism and Drug-drug Interactions in Adult Life

Stephanie Piekos  1 , Chad Pope  1 , Austin Ferrara  1 , Xiao-Bo Zhong  1
Affiliations

Impact of Drug Treatment at Neonatal Ages on Variability of Drug Metabolism and Drug-drug Interactions in Adult Life

Stephanie Piekos et al. Curr Pharmacol Rep. 2017 Feb.

Abstract

Purpose of review: As the number of patients taking more than one medication concurrently continues to increase, predicting and preventing drug-drug interactions (DDIs) is now more important than ever. Administration of one drug can cause changes in the expression and activity of drug metabolizing enzymes (DMEs) and alter the efficacy or toxicity of other medications that are substrates for these enzymes, resulting in a DDI. In today's medical practice, potential DDIs are evaluated based on the current medications a patient is taking with little regard to drugs the patient has been exposed to in the past. The purpose of this review is to discuss potential impacts of drug treatment at neonatal ages on the variability of drug metabolism and DDIs in adult life.

Recent findings: Existing evidence from the last thirty years has shown that exposure to certain xenobiotics during neonatal life has the potential to persistently alter DME expression through adult life. With recent advancements in the understanding of epigenetic regulation on gene expression, this phenomenon is resurfacing in the scientific community in hopes of defining possible mechanisms. Exposure to compounds that have the ability to bind nuclear receptors and trigger epigenetic modifications at neonatal and pediatric ages may have long-term, if not permanent, consequences on gene expression and DME activity.

Summary: The information summarized in this review should challenge the way current healthcare providers assess DDI potential and may offer an explanation to the significant interindividual variability in drug metabolism that is observed among patients.

Keywords: cytochrome P450; drug metabolism; drug-drug interactions; neonatal drug treatment; precision medicine.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest The authors declare that they have no conflict of interest.

References

    1. Rambhade S, Chakarborty A, Shrivastava A, Patil UK, Rambhade A. A survey on polypharmacy and use of inappropriate medications. Toxicology international. 2012;19(1):68–73. doi: 10.4103/0971-6580.94506. - DOI - PMC - PubMed
    1. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clinical pharmacokinetics. 1998;35(5):361–90. doi: 10.2165/00003088-199835050-00003. - DOI - PubMed
    1. Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug safety. 1993;9(1):51–9. - PubMed
    1. Lu Y, Shen D, Pietsch M, Nagar C, Fadli Z, Huang H, et al. A novel algorithm for analyzing drug-drug interactions from MEDLINE literature. Scientific reports. 2015;5:17357. doi: 10.1038/srep17357. - DOI - PMC - PubMed
    1. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC medicine. 2015;13:74. doi: 10.1186/s12916-015-0322-7. - DOI - PMC - PubMed

LinkOut - more resources